In cancers such as non-small-cell lung cancer (NSCLC), well-characterised genetic signatures have transformed management with tyrosine kinase inhibitors targeting EGFR mutations and next-generation ALK inhibitors addressing ALK mutations [47], resulting in significantly improved patient outcomes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.